SWOG clinical trial number
SWOG-8312

Megestrol Acetate and Aminoglutethimide/ Hydrocortisone In Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer

Closed
Phase
Accrual
96%
Published
Abbreviated Title
Megestrol Acetate and Aminoglutethimide/ Hydrocortisone In Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer
Activated
05/04/1984
Closed
11/15/1990

Research committees

Breast Cancer

Publication Information Expand/Collapse

2000

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint

R Mick;JJ Crowley;RJ Carroll Controlled Clinical Trials 21:343-359

1997

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group phase III trial.

CA Russell;SJ Green;J O'Sullivan;HE Hynes;GT Budd;JE Congdon;S Martino;CK Osborne Journal of Clinical Oncology 15(7):2494-2501

1991

Megesterol acetate (MA) and aminoglutethimide/hydrocortisone (AG) in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group study.

J Congdon;S Green;J O'Sullivan;HE Hynes;R Belt;K Gail;B Zidar;CK Osborne ASCO 10:43(#45)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase